Press Resease

Ovarian Cancer Market - Global Industry Analysis

Ovarian Cancer Market by Type (Epithelial Ovarian Tumors, Ovarian Germ Cell Tumors, Ovarian Stromal Tumors, and Primary Peritoneal Carcinoma), by Cancer Stage (Stage I, Stage II, Stage III, and Stage IV), by Diagnostics (Physical Examination, Biopsy, Blood Tests, Human Chorionic Gonadotropin (hCG) test, ultrasound, MRI, PET, and CT scans), and by Treatment (Chemotherapy, Targeted Therapy, Radiation Therapy, Immunotherapy, Hormonal Therapy, and Surgery): Global Industry Perspective, Comprehensive Analysis, and Forecast, 2017 - 2024

Published Date: 11-Aug-2018 Category: Pharmaceutical Report Format : PDF Pages: 110 Report Code: ZMR-3037 Status : Published

Global ovarian cancer market expected to generate revenue of around USD 4.01 billion by end of 2024, growing at a CAGR of around 11.82% between 2018 and 2024. Ovaries are located on each side of the uterus and are a part of the female reproductive system. Ovaries produce ovum and female hormones progesterone and estrogen.

Description

The report covers the forecast and analysis for the ovarian cancer market on a global and regional level. The study provides historical data from 2015 along with a forecast from 2018 to 2024 based on revenue (USD Billion). The study includes drivers and restraints for the ovarian cancer market along with the impact they have on the demand over the forecast period. Additionally, the report includes the study of opportunities available in the ovarian cancer market on a global level.
In order to give the users of this report a comprehensive view of the ovarian cancer market, we have included competitive landscape and analysis of Porter’s Five Forces model for the market. The study encompasses a market attractiveness analysis, where type, cancer stage, diagnostic, treatment, and regional segmentations are benchmarked based on their market size, growth rate, and general attractiveness.

The report provides company market share analysis in order to give a broader overview of the key players in the market. In addition, the report also covers key strategic developments of the market including acquisitions & mergers, new product launch, agreements, partnerships, collaborations & joint ventures, research & development, regional expansion of major participants involved in the market on the global and regional basis. 

Global Ovarian Cancer Market

The study provides a decisive view of the ovarian cancer market by segmenting the market based on type, cancer stage, diagnostic, treatment, and regions. All the segments have been analyzed based on present and future trends and the market is estimated from 2018 to 2024. 

The ovarian cancer market is classified based on type, cancer stage, diagnostic, treatment, and region. On the basis of type, the market is divided epithelial ovarian tumors, ovarian germ cell tumors, ovarian stromal tumors, and primary peritoneal carcinoma. On the basis of cancer stage market is segmented as Stage I, Stage II, Stage III, and Stage IV. On the basis of diagnostics, the market is divided into chemotherapy, targeted therapy, radiation therapy, human chorionic gonadotropin (hCG) test, ultrasound, MRI (Magnetic resonance imaging), PET (Positron emission tomography), and CT scans. On the basis of treatment, the market is divided into chemotherapy, targeted therapy, radiation therapy, immunotherapy, hormonal therapy, and surgery.

The regional segmentation includes the current and forecast demand for North America, Europe, Asia Pacific, Latin America, and The Middle East & Africa with its further bifurcation into major countries including the U.S., Germany, France, U.K., China, Japan, India, and Brazil. This segmentation includes demand for ovarian cancer market based on the individual segment in all the regions and countries.

The report also includes detailed profiles of end players such as Astra Zeneca Plc, Bristol Myers Squibb Company, Genentech Inc., Eli Lilly and Company, Novogen, Inc., GlaxoSmithKline Plc, Janssen Pharmaceuticals, Inc., Aetera Zenteris Inc., Boehringer Ingelheim GmbH, F. Hoffman-La Roche Ltd., and others.
 
This report segments the global ovarian cancer market as follows:

Global Ovarian Cancer Market: by Type

  • Epithelial Ovarian Tumors 
  • Ovarian Germ Cell Tumors
  • Ovarian Stromal Tumors 
  • Primary Peritoneal Carcinoma

Global Ovarian Cancer Market: by Cancer Stage

  • Stage I
  • Stage II
  • Stage III
  • Stage IV 

Global Ovarian Cancer Market: by Diagnostic

  • Chemotherapy
  • Targeted Therapy
  • Radiation Therapy

Human Chorionic Gonadotropin (hCG) test

  • Ultrasound
  • MRI
  • PET
  • CT scans

Global Ovarian Cancer Market: by Treatment

  • Chemotherapy
  • Targeted Therapy
  • Radiation Therapy
  • Immunotherapy
  • Hormonal Therapy
  • Surgery

Global Ovarian Cancer Market: by Region

  • North America
    • The U.S.
  • Europe
    • UK
    • France
    • Germany
  • Asia Pacific
    • China
    • Japan
    • India
  • Latin America
    • Brazil
  • The Middle East and Africa

Table Of Content

  • Chapter 1. Introduction
    • 1.1. Report description and scope
    • 1.2. Research scope
    • 1.3. Research methodology
      • 1.3.1. Market research process
      • 1.3.2. Market research methodology
  •  
  • Chapter 2. Executive Summary
    • 2.1. Global Ovarian Cancer Market, 2017-2024 (USD Billion)
    • 2.2. Global Ovarian Cancer Market: Snapshot
  •  
  • Chapter 3. Ovarian Cancer Market Dynamics
    • 3.1. Introduction
    • 3.2. Market drivers
      • 3.2.1. Global Ovarian Cancer Market drivers: Impact analysis
      • 3.2.2. Growing incidences of ovarian cancer worldwide
      • 3.2.3. Growing use of combination therapies for the treatment
    • 3.3. Market Restraints
      • 3.3.1. Launch of generic drugs
      • 3.3.2. Lack of accurate diagnosis of ovarian cancer
    • 3.4. Opportunities
      • 3.4.1. Developing new drugs for treating ovarian cancer
    • 3.5. Porter's five forces analysis
      • 3.5.1. Bargaining power of suppliers
      • 3.5.2. Bargaining power of buyers
      • 3.5.3. Threat from new entrants
      • 3.5.4. Threat from new substitutes
      • 3.5.5. Degree of competition
    • 3.6. Market attractiveness analysis
      • 3.6.1. Market attractiveness analysis, by Type
      • 3.6.2. Market attractiveness analysis, by Cancer Stage
      • 3.6.3. Market attractiveness analysis, by Diagnostic
      • 3.6.4. Market attractiveness analysis, by Treatment
      • 3.6.5. Market attractiveness analysis, by Regional Segment
  •  
  • Chapter 4. Global Ovarian Cancer Market - Competitive Landscape
    • 4.1. Company Market Share Analysis
      • 4.1.1. Global Ovarian Cancer Market: company market share, 2015
    • 4.2. Strategic Development
      • 4.2.1. Acquisitions & Mergers
      • 4.2.2. New Product Launch
      • 4.2.3. Agreements, Partnerships, Collaborations and Joint Ventures
      • 4.2.4. Research and Development, Regional Expansion
  •  
  • Chapter 5. Global Ovarian Cancer Market - Type Segment Analysis
    • 5.1. Global Ovarian Cancer Market: Type overview
      • 5.1.1. Global Ovarian Cancer Market revenue share, by Type, 2074 and 2024(USD Billion)
    • 5.2. Epithelial Ovarian Tumors
      • 5.2.1. Global Epithelial Ovarian Tumors market, 2017-2024(USD Billion)
    • 5.3. Ovarian Germ Cell Tumors
      • 5.3.1. Global Ovarian Germ cell Tumors market, 2017-2024(USD Billion)
    • 5.4. Ovarian Stromal Tumors
      • 5.4.1. Global Ovarian Stromal Tumors market, 2017-2024(USD Billion)
    • 5.5. Primary Peritoneal Carcinoma
      • 5.5.1. Global Primary Peritoneal Carcinoma market, 2017-2024(USD Billion)
  •  
  • Chapter 6. Global Ovarian Cancer Market - Cancer Stage Segment Analysis
    • 6.1. Global Ovarian Cancer Market: Cancer Stage overview
      • 6.1.1. Global Ovarian Cancer Market revenue share, by Cancer Stage, 2074 and 2024(USD Billion)
    • 6.2. Stage I
      • 6.2.1. Global Ovarian Cancer Market for Stage I, 2017-2024(USD Billion)
    • 6.3. Stage II
      • 6.3.1. Global Ovarian Cancer Market for Stage II, 2017-2024(USD Billion)
    • 6.4. Stage III
      • 6.4.1. Global Ovarian Cancer Market for Stage III, 2017-2024(USD Billion)
    • 6.5. Stage IV
      • 6.5.1. Global Ovarian Cancer Market for Stage IV, 2017-2024(USD Billion)
  •  
  • Chapter 7. Global Ovarian Cancer Market - Diagnostic Segment Analysis
    • 7.1. Global Ovarian Cancer Market: Diagnostic overview
      • 7.1.1. Global Ovarian Cancer Market revenue share, by Diagnostic, 2074 and 2024(USD Billion)
    • 7.2. Physical Examination
      • 7.2.1. Global Ovarian Cancer Market for Physical Examination, 2017-2024(USD Billion)
    • 7.3. Biopsy
      • 7.3.1. Global Ovarian Cancer Market for Biopsy, 2017-2024(USD Billion)
    • 7.4. Blood Tests
      • 7.4.1. Global Ovarian Cancer Market for Blood Tests, 2017-2024(USD Billion)
    • 7.5. Human Chorionic Gonadotropin (hCG) Test
      • 7.5.1. Global Ovarian Cancer Market for Human Chorionic Gonadotropin (hCG) Tests, 2017-2024(USD Billion)
    • 7.6. Ultrasound
      • 7.6.1. Global Ovarian Cancer Market for Ultrasound, 2017-2024(USD Billion)
    • 7.7. MRI
      • 7.7.1. Global Ovarian Cancer Market for MRI, 2017-2024(USD Billion)
    • 7.8. PET
      • 7.8.1. Global Ovarian Cancer Market for PET, 2017-2024(USD Billion)
    • 7.9. CT scans
      • 7.9.1. Global Ovarian Cancer Market for CT scans, 2017-2024(USD Billion)
  •  
  • Chapter 8. Global Ovarian Cancer Market - Treatment Segment Analysis
    • 8.1. Global Ovarian Cancer Market: Diagnostic overview
      • 8.1.1. Global Ovarian Cancer Market revenue share, by Diagnostic, 2074 and 2024(USD Billion)
    • 8.2. Chemotherapy
      • 8.2.1. Global Ovarian Cancer Market for Chemotherapy, 2017-2024(USD Billion)
    • 8.3. Targeted Therapy
      • 8.3.1. Global Ovarian Cancer Market for Targeted Therapy, 2017-2024(USD Billion)
    • 8.4. Radiation Therapy
      • 8.4.1. Global Ovarian Cancer Market for Radiation Therapy, 2017-2024(USD Billion)
    • 8.5. Immunotherapy
      • 8.5.1. Global Ovarian Cancer Market for Immunotherapy, 2017-2024(USD Billion)
    • 8.6. Hormonal Therapy
      • 8.6.1. Global Ovarian Cancer Market for Hormonal Therapy, 2017-2024(USD Billion)
    • 8.7. Surgery
      • 8.7.1. Global Ovarian Cancer Market for Surgery, 2017-2024(USD Billion)
  •  
  • Chapter 9. Global Ovarian Cancer Market - Regional Segment Analysis
    • 9.1. Global Ovarian Cancer Market: Regional overview
      • 9.1.1. Global Ovarian Cancer Market revenue share, by Region, 2015 and 2021
    • 9.2. North America
      • 9.2.1. North America Ovarian Cancer Market revenue, by Type, 2017-2024(USD Billion)
      • 9.2.2. North America Ovarian Cancer Market revenue, by Cancer Stage, 2017-2024(USD Billion)
      • 9.2.3. North America Ovarian Cancer Market revenue, by Diagnostic, 2017-2024(USD Billion)
      • 9.2.4. North America Ovarian Cancer Market revenue, by Treatment, 2017-2024(USD Billion)
      • 9.2.5. North America Ovarian Cancer Market revenue, by Region, 2017-2024(USD Billion)
      • 9.2.6. The U.S.
        • 9.2.6.1. The U.S. Ovarian Cancer Market revenue, by Type, 2017-2024(USD Billion)
        • 9.2.6.2. The U.S. Ovarian Cancer Market revenue, by Cancer Stage, 2017-2024(USD Billion)
        • 9.2.6.3. The U.S. Ovarian Cancer Market revenue, by Diagnostic, 2017-2024(USD Billion)
        • 9.2.6.4. The U.S. Ovarian Cancer Market revenue, by Treatment, 2017-2024(USD Billion)
        • 9.2.6.5. The U.S. Ovarian Cancer Market revenue, by Region, 2017-2024(USD Billion)
      • 9.2.7. Rest of North America
        • 9.2.7.1. Rest of North America Ovarian Cancer Market revenue, by Type, 2017-2024(USD Billion)
        • 9.2.7.2. Rest of North America Ovarian Cancer Market revenue, by Cancer Stage, 2017-2024(USD Billion)
        • 9.2.7.3. Rest of North America Ovarian Cancer Market revenue, by Diagnostic, 2017-2024(USD Billion)
        • 9.2.7.4. Rest of North America Ovarian Cancer Market revenue, by Treatment, 2017-2024(USD Billion)
        • 9.2.7.5. Rest of North America Ovarian Cancer Market revenue, by Region, 2017-2024(USD Billion)
    • 9.3. Europe
      • 9.3.1. Europe Ovarian Cancer Market revenue, by Type, 2017-2024(USD Billion)
      • 9.3.2. Europe Ovarian Cancer Market revenue, by Cancer Stage, 2017-2024(USD Billion)
      • 9.3.3. Europe Ovarian Cancer Market revenue, by Diagnostic, 2017-2024(USD Billion)
      • 9.3.4. Europe Ovarian Cancer Market revenue, by Treatment, 2017-2024(USD Billion)
      • 9.3.5. Europe Ovarian Cancer Market revenue, by Region, 2017-2024(USD Billion)
      • 9.3.6. Germany
        • 9.3.6.1. Germany Ovarian Cancer Market revenue, by Type, 2017-2024(USD Billion)
        • 9.3.6.2. Germany Ovarian Cancer Market revenue, by Cancer Stage, 2017-2024(USD Billion)
        • 9.3.6.3. Germany Ovarian Cancer Market revenue, by Diagnostic, 2017-2024(USD Billion)
        • 9.3.6.4. Germany Ovarian Cancer Market revenue, by Treatment, 2017-2024(USD Billion)
        • 9.3.6.5. Germany Ovarian Cancer Market revenue, by Region, 2017-2024(USD Billion)
      • 9.3.7. U.K.
        • 9.3.7.1. U.K. Ovarian Cancer Market revenue, by Type, 2017-2024(USD Billion)
        • 9.3.7.2. U.K. Ovarian Cancer Market revenue, by Cancer Stage, 2017-2024(USD Billion)
        • 9.3.7.3. U.K. Ovarian Cancer Market revenue, by Diagnostic, 2017-2024(USD Billion)
        • 9.3.7.4. U.K. Ovarian Cancer Market revenue, by Treatment, 2017-2024(USD Billion)
        • 9.3.7.5. U.K. Ovarian Cancer Market revenue, by Region, 2017-2024(USD Billion)
      • 9.3.8. France
        • 9.3.8.1. France Ovarian Cancer Market revenue, by Type, 2017-2024(USD Billion)
        • 9.3.8.2. France Ovarian Cancer Market revenue, by Cancer Stage, 2017-2024(USD Billion)
        • 9.3.8.3. France Ovarian Cancer Market revenue, by Diagnostic, 2017-2024(USD Billion)
        • 9.3.8.4. France Ovarian Cancer Market revenue, by Treatment, 2017-2024(USD Billion)
        • 9.3.8.5. France Ovarian Cancer Market revenue, by Region, 2017-2024(USD Billion)
      • 9.3.9. Rest of Europe
        • 9.3.9.1. Rest of Europe Ovarian Cancer Market revenue, by Type, 2017-2024(USD Billion)
        • 9.3.9.2. Rest of Europe Ovarian Cancer Market revenue, by Cancer Stage, 2017-2024(USD Billion)
        • 9.3.9.3. Rest of Europe Ovarian Cancer Market revenue, by Diagnostic, 2017-2024(USD Billion)
        • 9.3.9.4. Rest of Europe Ovarian Cancer Market revenue, by Treatment, 2017-2024(USD Billion)
        • 9.3.9.5. Rest of Europe Ovarian Cancer Market revenue, by Region, 2017-2024(USD Billion)
    • 9.4. Asia Pacific
      • 9.4.1. Asia Pacific Ovarian Cancer Market revenue, by Type, 2017-2024(USD Billion)
      • 9.4.2. Asia Pacific Ovarian Cancer Market revenue, by Cancer Stage, 2017-2024(USD Billion)
      • 9.4.3. Asia Pacific Ovarian Cancer Market revenue, Diagnostic, 2017-2024(USD Billion)
      • 9.4.4. Asia Pacific Ovarian Cancer Market revenue, by Treatment, 2017-2024(USD Billion)
      • 9.4.5. Asia Pacific Ovarian Cancer Market revenue, by Region, 2017-2024(USD Billion)
      • 9.4.6. China
        • 9.4.6.1. China Ovarian Cancer Market revenue, by Type, 2017-2024(USD Billion)
        • 9.4.6.2. China Ovarian Cancer Market revenue, by Cancer Stage, 2017-2024(USD Billion)
        • 9.4.6.3. China Ovarian Cancer Market revenue, by Diagnostic, 2017-2024(USD Billion)
        • 9.4.6.4. China Ovarian Cancer Market revenue, by Treatment, 2017-2024(USD Billion)
        • 9.4.6.5. China Ovarian Cancer Market revenue, by Region, 2017-2024(USD Billion)
      • 9.4.7. Japan
        • 9.4.7.1. Japan Ovarian Cancer Market revenue, by Type, 2017-2024(USD Billion)
        • 9.4.7.2. Japan Ovarian Cancer Market revenue, by Cancer Stage, 2017-2024(USD Billion)
        • 9.4.7.3. Japan Ovarian Cancer Market revenue, by Diagnostic, 2017-2024(USD Billion)
        • 9.4.7.4. Japan Ovarian Cancer Market revenue, by Treatment, 2017-2024(USD Billion)
        • 9.4.7.5. Japan Ovarian Cancer Market revenue, by region, 2017-2024(USD Billion)
      • 9.4.8. India
        • 9.4.8.1. India Ovarian Cancer Market revenue, by Type, 2017-2024(USD Billion)
        • 9.4.8.2. India Ovarian Cancer Market revenue, by Cancer Stage, 2017-2024(USD Billion)
        • 9.4.8.3. India Ovarian Cancer Market revenue, by Diagnostic, 2017-2024(USD Billion)
        • 9.4.8.4. India Ovarian Cancer Market revenue, by Treatment, 2017-2024(USD Billion)
        • 9.4.8.5. India Ovarian Cancer Market revenue, by region, 2017-2024(USD Billion)
      • 9.4.9. Rest of Asia Pacific
        • 9.4.9.1. Rest of Asia Pacific Ovarian Cancer Market revenue, by Type, 2017-2024(USD Billion)
        • 9.4.9.2. Rest of Asia Pacific Ovarian Cancer Market revenue, by Cancer Stage, 2017-2024(USD Billion)
        • 9.4.9.3. Rest of Asia Pacific Ovarian Cancer Market revenue, by Diagnostic, 2017-2024(USD Billion)
        • 9.4.9.4. Rest of Asia Pacific Ovarian Cancer Market revenue, by Treatment, 2017-2024(USD Billion)
        • 9.4.9.5. Rest of Asia Pacific Ovarian Cancer Market revenue, by region, 2017-2024(USD Billion)
    • 9.5. Latin America
      • 9.5.1. Latin America Ovarian Cancer Market revenue, by Type, 2017-2024(USD Billion)
      • 9.5.2. Latin America Ovarian Cancer Market revenue, by Cancer Stage, 2017-2024(USD Billion)
      • 9.5.3. Latin America Ovarian Cancer Market revenue, by Diagnostic, 2017-2024(USD Billion)
      • 9.5.4. Latin America Ovarian Cancer Market revenue, by Treatment, 2017-2024(USD Billion)
      • 9.5.5. Latin America Ovarian Cancer Market revenue, by Region, 2017-2024(USD Billion)
      • 9.5.6. Brazil
        • 9.5.6.1. Brazil Ovarian Cancer Market revenue, by Type, 2017-2024(USD Billion)
        • 9.5.6.2. Brazil Ovarian Cancer Market revenue, by Cancer Stage, 2017-2024(USD Billion)
        • 9.5.6.3. Brazil Ovarian Cancer Market revenue, by Diagnostic, 2017-2024(USD Billion)
        • 9.5.6.4. Brazil Ovarian Cancer Market revenue, by Treatment, 2017-2024(USD Billion)
        • 9.5.6.5. Brazil Ovarian Cancer Market revenue, by Region, 2017-2024(USD Billion)
      • 9.5.7. Rest of Latin America
        • 9.5.7.1. Rest of Latin America Ovarian Cancer Market revenue, by Type, 2017-2024(USD Billion)
        • 9.5.7.2. Rest of Latin America Ovarian Cancer Market revenue, by Cancer Stage, 2017-2024(USD Billion)
        • 9.5.7.3. Rest of Latin America Ovarian Cancer Market revenue, by Diagnostic, 2017-2024(USD Billion)
        • 9.5.7.4. Rest of Latin America Ovarian Cancer Market revenue, by Treatment, 2017-2024(USD Billion)
        • 9.5.7.5. Rest of Latin America Ovarian Cancer Market revenue, by Region, 2017-2024(USD Billion)
    • 9.6. The Middle East and Africa
      • 9.6.1. The Middle East and Africa Ovarian Cancer Market revenue, by Type, 2017-2024(USD Billion)
      • 9.6.2. The Middle East and Africa Ovarian Cancer Market revenue, by Cancer Stage, 2017-2024(USD Billion)
      • 9.6.3. The Middle East and Africa Ovarian Cancer Market revenue, by Diagnostic, 2017-2024(USD Billion)
      • 9.6.4. The Middle East and Africa Ovarian Cancer Market revenue, by Treatment, 2017-2024(USD Billion)
      • 9.6.5. The Middle East and Africa Ovarian Cancer Market revenue, by Region, 2017-2024(USD Billion)
  •  
  • Chapter 10. Company Profile
    • 10.1. Astra Zeneca plc.
      • 10.1.1. Overview
      • 10.1.2. Financials
      • 10.1.3. Therapy portfolio
      • 10.1.4. Business strategy
      • 10.1.5. Recent developments
    • 10.2. Bristol Myers Squibb Company
      • 10.2.1. Overview
      • 10.2.2. Financials
      • 10.2.3. Therapy portfolio
      • 10.2.4. Business strategy
      • 10.2.5. Recent developments
    • 10.3. Genentech Inc.
      • 10.3.1. Overview
      • 10.3.2. Financials
      • 10.3.3. Therapy portfolio
      • 10.3.4. Business strategy
      • 10.3.5. Recent developments
    • 10.4. Eli Lilly and Company
      • 10.4.1. Overview
      • 10.4.2. Financials
      • 10.4.3. Therapy portfolio
      • 10.4.4. Business strategy
      • 10.4.5. Recent developments
    • 10.5. Novogen, Inc.
      • 10.5.1. Overview
      • 10.5.2. Financials
      • 10.5.3. Therapy portfolio
      • 10.5.4. Business strategy
      • 10.5.5. Recent developments
    • 10.6. GlaxoSmithKline Plc
      • 10.6.1. Overview
      • 10.6.2. Financials
      • 10.6.3. Therapy portfolio
      • 10.6.4. Business strategy
      • 10.6.5. Recent developments
    • 10.7. Airgas, Inc.
      • 10.7.1. Overview
      • 10.7.2. Financials
      • 10.7.3. Therapy portfolio
      • 10.7.4. Business strategy
      • 10.7.5. Recent developments
    • 10.8. Janssen Pharmaceuticals, Inc.
      • 10.8.1. Overview
      • 10.8.2. Financials
      • 10.8.3. Therapy portfolio
      • 10.8.4. Business strategy
      • 10.8.5. Recent developments
    • 10.9. Aetera Zenteris Inc.
      • 10.9.1. Overview
      • 10.9.2. Financials
      • 10.9.3. Therapy portfolio
      • 10.9.4. Business strategy
      • 10.9.5. Recent developments
    • 10.10. Boehringer Ingelheim GmbH
      • 10.10.1. Overview
      • 10.10.2. Financials
      • 10.10.3. Therapy portfolio
      • 10.10.4. Business strategy
      • 10.10.5. Recent developments

List of Figures 

1. Market research process
2. Market research methodology
3. Global Ovarian Cancer Market revenue, 2017-2024 (USD Billion) 
4. Porter’s five forces analysis
5. Ovarian Cancer Market attractiveness analysis, by Type segment
6. Ovarian Cancer Market attractiveness analysis, by Cancer Stage segment
7. Ovarian Cancer Market attractiveness analysis, by Diagnostic segment
8. Ovarian Cancer Market attractiveness analysis, by Treatment segment
9. Ovarian Cancer Market: Market attractiveness analysis, by Regional segment
10. Company market share analysis, 2015 
11. Global Ovarian Cancer Market revenue share by Type, 2074 and 2024
12.  Global Epithelial Ovarian Tumors Market, 2017-2024 (USD Billion)
13. Global Ovarian Germ Cell Tumors Market, 2017-2024 (USD Billion)
14. Global Ovarian Stromal Tumors Market, 2017-2024 (USD Billion)
15. Global Primary Peritoneal Carcinoma Market, 2017-2024 (USD Billion)
16. Global Ovarian Cancer Market revenue share by Cancer Stage, 2074 and 2024
17. Global Ovarian Cancer Market, 2017-2024 (USD Billion)
a. Stage I, 2017-2024(USD Billion)
b. Stage II, 2017-2024(USD Billion)
c. Stage III, 2017-2024(USD Billion)
d. Stage IV, 2017-2024(USD Billion)
18. Global Ovarian Cancer Market revenue share by Diagnostic, 2074 and 2024
19. Global Ovarian Cancer Market, 2017-2024 (USD Billion)
a. Global Physical Examination Market, 2017-2024(USD Billion)
b. Global Biopsy Market, 2017-2024(USD Billion)
c. Global Blood Tests Market, 2017-2024(USD Billion)
d. Global Human Chorionic Gonadotropin (hCG) Test Market, 2017-2024(USD Billion)
e. Global Ultrasound Market, 2017-2024(USD Billion)
f. Global MRI Market, 2017-2024(USD Billion)
g. Global PET Market, 2017-2024(USD Billion)
h. Global CT scans Market, 2017-2024(USD Billion)
20. Global Ovarian Cancer Market revenue share by Treatment, 2017 and 2024
21. Global Ovarian Cancer Market, 2017-2024 (USD Billion)
a. Global Chemotherapy market, 2017-2024(USD Billion)
b. Global Targeted Therapy market, 2017-2024(USD Billion)
c. Global Radiation Therapy market, 2017-2024(USD Billion)
d. Global Immunotherapy market, 2017-2024(USD Billion)
e. Global Hormonal Therapy market, 2017-2024(USD Billion)
f. Global Surgery market, 2017-2024(USD Billion)


List of Tables

1. Ovarian Cancer Market: Market Snapshot                                                                                                                        
2. Drivers of global Ovarian Cancer Market: Impact analysis 
3. Restraints of Ovarian Cancer Market: Impact analysis  
4. North America Ovarian Cancer Market revenue, by Type, 2017-2024(USD Billion) 
5. North America Ovarian Cancer Market revenue, by Cancer Stage, 2017-2024(USD Billion) 
6. North America Ovarian Cancer Market revenue, by Diagnostic, 2017-2024(USD Billion) 
7. North America Ovarian Cancer Market revenue, by Treatment, 2017-2024(USD Billion) 
8. North America Ovarian Cancer Market revenue, by Region, 2017-2024(USD Billion)
9. The U.S. Ovarian Cancer Market revenue, by Type, 2017-2024(USD Billion) 
10. The U.S. Ovarian Cancer Market revenue, by Cancer Stage, 2017-2024(USD Billion)
11.  The U.S. Ovarian Cancer Market revenue, by Diagnostic, 2017-2024(USD Billion)
12. The U.S. Ovarian Cancer Market revenue, by Treatment, 2017-2024(USD Billion)
13. The U.S. Ovarian Cancer Market revenue, by Region, 2017-2024(USD Billion)
14. Rest of North America Ovarian Cancer Market revenue, by Type, 2017-2024(USD Billion) 
15. Rest of North America Ovarian Cancer Market revenue, by Cancer Stage, 2017-2024(USD Billion) 
16. Rest of North America Ovarian Cancer Market revenue, by Diagnostic, 2017-2024(USD Billion)
17. Rest of North America Ovarian Cancer Market revenue, by Treatment, 2017-2024(USD Billion)
18. Rest of North America Ovarian Cancer Market revenue, by Region, 2017-2024(USD Billion)
19. Europe Ovarian Cancer Market revenue, by Type, 2017-2024(USD Billion)
20. Europe Ovarian Cancer Market revenue, by Cancer Stage, 2017-2024(USD Billion)
21. Europe Ovarian Cancer Market revenue, by Diagnostic, 2017-2024(USD Billion)
22. Europe Ovarian Cancer Market revenue, by Treatment, 2017-2024(USD Billion)
23. Europe Ovarian Cancer Market revenue, by Region, 2017-2024(USD Billion)
24. Germany Ovarian Cancer Market revenue, by Type, 2017-2024(USD Billion)
25. Germany Ovarian Cancer Market revenue, by Cancer Stage, 2017-2024(USD Billion)
26. Germany Ovarian Cancer Market revenue, by Diagnostic, 2017-2024(USD Billion)
27. Germany Ovarian Cancer Market revenue, by Treatment, 2017-2024(USD Billion)
28. Germany Ovarian Cancer Market revenue, by Region, 2017-2024(USD Billion)
29. U.K. Ovarian Cancer Market revenue, by Type, 2017-2024(USD Billion)
30. U.K. Ovarian Cancer Market revenue, by Cancer Stage, 2017-2024(USD Billion)
31. U.K. Ovarian Cancer Market revenue, by Diagnostic, 2017-2024(USD Billion)
32. U.K. Ovarian Cancer Market revenue, by Region, 2017-2024(USD Billion)
33. France Ovarian Cancer Market revenue, by Type, 2017-2024(USD Billion) 
34. France Ovarian Cancer Market revenue, by Cancer Stage, 2017-2024(USD Billion) 
35. France Ovarian Cancer Market revenue, by Diagnostic, 2017-2024(USD Billion) 
36. France Ovarian Cancer Market revenue, by Treatment, 2017-2024(USD Billion) 
37. France Ovarian Cancer Market revenue, by Region, 2017-2024(USD Billion)
38. Rest of Europe Ovarian Cancer Market revenue, by Type, 2017-2024(USD Billion)
39. Rest of Europe Ovarian Cancer Market revenue, by Cancer Stage, 2017-2024(USD Billion)
40. Rest of Europe Ovarian Cancer Market revenue, by Diagnostic, 2017-2024(USD Billion)
41. Rest of Europe Ovarian Cancer Market revenue, by Treatment, 2017-2024(USD Billion)
42. Rest of Europe Ovarian Cancer Market revenue, by Region, 2017-2024(USD Billion)
43. Asia Pacific Ovarian Cancer Market revenue, by Type, 2017-2024(USD Billion)
44. Asia Pacific Ovarian Cancer Market revenue, by Cancer Stage, 2017-2024(USD Billion)
45. Asia Pacific Ovarian Cancer Market revenue, by Diagnostic, 2017-2024(USD Billion)
46. Asia Pacific Ovarian Cancer Market revenue, by Treatment, 2017-2024(USD Billion)
47. Asia Pacific Ovarian Cancer Market revenue, by Region, 2017-2024(USD Billion)
48. China Ovarian Cancer Market revenue, by Type, 2017-2024(USD Billion) 
49. China Ovarian Cancer Market revenue, by Cancer Stage, 2017-2024(USD Billion) 
50. China Ovarian Cancer Market revenue, by Diagnostic, 2017-2024(USD Billion) 
51. China Ovarian Cancer Market revenue, by Treatment, 2017-2024(USD Billion) 
52. China Ovarian Cancer Market revenue, by Region, 2017-2024(USD Billion)
53. Japan Ovarian Cancer Market revenue, by Type, 2017-2024(USD Billion)
54. Japan Ovarian Cancer Market revenue, by Cancer Stage, 2017-2024(USD Billion) 
55. Japan Ovarian Cancer Market revenue, by Diagnostic, 2017-2024(USD Billion) 
56. Japan Ovarian Cancer Market revenue, by Treatment, 2017-2024(USD Billion)
57. Japan Ovarian Cancer Market revenue, by Region, 2017-2024(USD Billion)
58. India Ovarian Cancer Market revenue, by Type, 2017-2024(USD Billion)
59. India Ovarian Cancer Market revenue, by Cancer Stage, 2017-2024(USD Billion)
60. India Ovarian Cancer Market revenue, by Diagnostic, 2017-2024(USD Billion)
61. India Ovarian Cancer Market revenue, by Treatment, 2017-2024(USD Billion)
62. India Ovarian Cancer Market revenue, by region, 2017-2024(USD Billion)
63. Rest of Asia Pacific Ovarian Cancer Market revenue, by Type, 2017-2024(USD Billion) 
64. Rest of Asia Pacific Ovarian Cancer Market revenue, by Cancer Stage, 2017-2024(USD Billion)
65. Rest of Asia Pacific Ovarian Cancer Market revenue, by Diagnostic, 2017-2024(USD Billion)
66. Rest of Asia Pacific Ovarian Cancer Market revenue, by Treatment, 2017-2024(USD Billion)
67. Rest of Asia Pacific Ovarian Cancer Market revenue, by Region, 2017-2024(USD Billion)
68. Latin America Ovarian Cancer Market revenue, by Type, 2017-2024(USD Billion) 
69. Latin America Ovarian Cancer Market revenue, by Cancer Stage, 2017-2024(USD Billion)  
70. Latin America Ovarian Cancer Market revenue, by Diagnostic, 2017-2024(USD Billion)  
71. Latin America Ovarian Cancer Market revenue, by Treatment, 2017-2024(USD Billion)  
72. Latin America Ovarian Cancer Market revenue, by Region, 2017-2024(USD Billion)
73. Brazil Ovarian Cancer Market revenue, by Type, 2017-2024(USD Billion) 
74. Brazil Ovarian Cancer Market revenue, by Cancer Stage, 2017-2024(USD Billion) 
75. Brazil Ovarian Cancer Market revenue, by Diagnostic, 2017-2024(USD Billion) 
76. Brazil Ovarian Cancer Market revenue, by Treatment, 2017-2024(USD Billion) 
77. Brazil Ovarian Cancer Market revenue, by Region, 2017-2024(USD Billion) 
78. Rest of Latin America Ovarian Cancer Market revenue, by Type, 2017-2024(USD Billion) 
79. Rest of Latin America Ovarian Cancer Market revenue, by Cancer Stage, 2017-2024(USD Billion) 
80. Rest of Latin America Ovarian Cancer Market revenue, by Diagnostic, 2017-2024(USD Billion) 
81. Rest of Latin America Ovarian Cancer Market revenue, by Treatment, 2017-2024(USD Billion) 
82. Rest of Latin America Ovarian Cancer Market revenue, by Region, 2017-2024(USD Billion)
83. The Middle East and Africa Ovarian Cancer Market revenue, by Type, 2017-2024(USD Billion) 
84. The Middle East and Africa Ovarian Cancer Market revenue, by Cancer Stage, 2017-2024(USD Billion)  
85. The Middle East and Africa Ovarian Cancer Market revenue, by Diagnostic, 2017-2024(USD Billion)  
86. The Middle East and Africa Ovarian Cancer Market revenue, by Treatment, 2017-2024(USD Billion)  
87. The Middle East and Africa Ovarian Cancer Market revenue, by Region, 2017-2024(USD Billion) 

Methodology

Free Analysis

Ovaries are located on each side of the uterus and are a part of the female reproductive system. Ovaries produce ovum and female hormones progesterone and estrogen. These female hormones manage the menstrual cycle along with influencing the development of female body characteristics. In normal conditions, human cells undergo division and fusion that results in the formation of new cells. New cells take the place of old or damaged cells. However, this process is disturbed when cancer develops. In cancer, the old or damaged cells survive and new cells keep appearing. This abnormality could lead to the formation of a tumor, a mass of cells. Ovarian cancer is a disease which involves the abnormal or cancerous growth of the cells in the ovaries. There are four major types of ovarian cancer: Epithelial ovarian cancer, Borderline tumors, Germ cell ovarian cancer, and Sex-cord stromal cell cancer. The cancer types are determined based on the location of the ovarian cells where the cancerous growth starts. After starting from ovaries, ovarian cancer spreads to the pelvis and abdomen region. Ovarian cancer is virtually undetectable when it is in the ovaries.

According to World Cancer Research Fund International, ovarian cancer comes in at the eighteenth number on the list of most common cancer and on the seventh number in the list of common cancer in women. The highest occurrence of ovarian cancer is found in North America and Europe. As per the estimates are given by American Cancer Society for the year 2018, in the United States around 22,400 women are expected to receive ovarian cancer diagnosis and around 14,070 ovarian cancer deaths will occur. Ovarian cancer causes more deaths than any other female reproductive system cancers. Ovarian cancer is the fifth leading cause of death due to cancer in women. About 1 in 78 women are at the risk of getting ovarian cancer. Women in the age group of 50 to 60 years are at a higher risk of getting ovarian cancer.

Global Ovarian Cancer Market

The strongest risk factors that can cause ovarian cancer are acquired genetic changes, genetic mutations called BRCA1 or BRCA2, old age, obesity, not having a full-term pregnancy, using fertility treatment, hormone therapy post menopause, and PTEN tumor hamartoma syndrome.

Factors such as increasing geriatric population of women rise in ovarian cancer cases, availability of new drugs and therapies, increase in healthcare expenditure, and increased government funding are expected to boost the growth of ovarian cancer market. However, availability of generic drugs and patent expiration of branded drugs can act as a restraint in the growth of the ovarian cancer market. The lack of precise diagnostic techniques for ovarian cancer in the early stages can also have a negative impact on the global ovarian cancer market.

On the basis of the type the ovarian cancer market has been divided into epithelial ovarian tumors, ovarian germ cell tumors, ovarian stromal tumors, and primary peritoneal carcinoma. On the basis of the cancer stage, the market is segmented into Stage I, Stage II, Stage III, and Stage IV. On the basis of diagnostics, the market divided into the physical examination, biopsy, blood tests, Human Chorionic Gonadotropin (HCG) test, ultrasound, MRI (Magnetic resonance imaging), PET (Positron emission tomography), and CT scans. On the basis of treatment, the market divided into chemotherapy, targeted therapy, radiation therapy, immunotherapy, hormonal therapy, and surgery. In the forecast period, the diagnostic segment will dominate the global market as ovarian cancer is most chemosensitive cancer.

North America will be the dominant region during the forecast period. Increasing prevalence of ovarian cancer in the region and availability of latest diagnostic methods are the factors that will boost the ovarian cancer market in this region. Europe will be the second largest market. The Asia Pacific will grow at the fastest rate over the forecast period. Increasing healthcare expenditure and growing attention towards ovarian cancer diagnosis are the driving factors for the growth of the ovarian cancer market in this region. Latin America market is projected to grow at a moderate rate during the forecast period. The Middle East and Africa are expected to experience noticeable growth in the years to come.

Some of the key players in ovarian cancer market include Astra Zeneca Plc, Bristol Myers Squibb Company, Genentech Inc., Eli Lilly and Company, Novogen, Inc., GlaxoSmithKline Plc, Janssen Pharmaceuticals, Inc., Aetera Zenteris Inc., Boehringer Ingelheim GmbH, F. Hoffman-La Roche Ltd., and others.

Choose License Type

Request the coronavirus impact analysis across industries and markets

HappyClients

Office Address

Corporate Office

Zion Market Research 244 Fifth Avenue, Suite N202 New York, 10001, United States
Tel: +1 (844) 845-5245
USA/Canada Toll Free No.+1 (855) 465-4651

Asia Pacific Office

3rd Floor, Mrunal Paradise, Opp Maharaja Hotel, Pimple Gurav, Pune 411061, Maharashtra, India
Phone No 020-46277770

Contact #

US OFFICE NO +1 (844) 845-5245
US/CAN TOLL FREE +1 (855) 465-4651
Email: sales@zionmarketresearch.com

We Are On Social